Immuneering Overview

  • Founded
  • 2008
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 60
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $62M
Latest Deal Amount
  • Investors
  • 8

Immuneering General Information

Description

Developer of a disease canceling technology designed to forge a new approach to drug discovery, develop transformative medicines, and help others make the most of their data. The company's technology is focused on treating aspects of the disease that have eluded conventional approaches, including cancer cachexia and metastasis, enabling clients in the healthcare sectors to manufacture drugs to counteract several critical diseases.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Primary Office
  • 245 Main Street
  • 2nd Floor
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immuneering Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 05-Jan-2021 $62M 0000 Completed Pre-Clinical Trials
2. Later Stage VC (Series A) 16-Dec-2019 0000 0000 0000 Completed Pre-Clinical Trials
1. Merger/Acquisition 30-Sep-2015 $60M 00000 Completed Pre-Clinical Trials
To view Immuneering’s complete valuation and funding history, request access »

Immuneering Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Immuneering’s complete cap table history, request access »

Immuneering Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a disease canceling technology designed to forge a new approach to drug discovery, develop transformative m
Drug Discovery
Cambridge, MA
60 As of 2021
0000
00000000000 0000

000000 0

ip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum do
0000 000000000
Brisbane, CA
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00

00000000

a pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt molli
0000 000000000
Houston, TX
00 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immuneering Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Second Genome Venture Capital-Backed Brisbane, CA 00 000.00 00000000000 000.00
00000000 Venture Capital-Backed Houston, TX 00 00.000 0000000000 0 00.000
0000000000 Formerly VC-backed Menlo Park, CA 000 00000 00000000 00000
000000000 Venture Capital-Backed Ann Arbor, MI 00 000.00 0000000000 0 000.00
00000000 Formerly VC-backed San Diego, CA 0000 00000 000000&0
You’re viewing 5 of 11 competitors. Get the full list »

Immuneering Executive Team (6)

Name Title Board Seat Contact Info
Benjamin Zeskind Ph.D Co-Founder, Chief Executive Officer and Board Member
Rebecca Kusko Ph.D Chief Strategy Officer
Brett Hall Chief Scientific Officer
Carolina Rizo Ph.D Chief Business Officer
Bob Carpenter Co-Founder & Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

Immuneering Board Members (3)

Name Representing Role Since
Bob Carpenter Immuneering Co-Founder & Board Member 000 0000
Joseph Kekst Self Board Member 000 0000
Peter Feinberg Self Board Observer 000 0000
To view Immuneering’s complete board members history, request access »

Immuneering Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial